{"id":"artemether-lumefantrine-p-falciparum","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Vomiting"},{"rate":"6%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297927","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Artemether-lumefantrine is a combination therapy used to treat uncomplicated Plasmodium falciparum malaria. Artemether is a potent inhibitor of the parasite's mitochondrial electron transport chain, while lumefantrine is a potent inhibitor of the parasite's heme detoxification pathway.","oneSentence":"Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:34:58.723Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated Plasmodium falciparum malaria"}]},"trialDetails":[{"nctId":"NCT05842954","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-07","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1720},{"nctId":"NCT05979207","phase":"PHASE1","title":"Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2023-08-01","conditions":"Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome","enrollment":12},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":"Malaria, Vivax","enrollment":1991},{"nctId":"NCT05287893","phase":"PHASE1","title":"Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2022-04-04","conditions":"Malaria,Falciparum, Malaria, Malaria Recrudescence","enrollment":10},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Malaria","enrollment":16},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04079621","phase":"PHASE4","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-10-27","conditions":"Malaria, Malaria, Vivax, Malaria,Falciparum","enrollment":27},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT01614964","phase":"PHASE2","title":"Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-08","conditions":"Malaria","enrollment":66},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT02389374","phase":"PHASE4","title":"A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2014-08","conditions":"Malaria","enrollment":181},{"nctId":"NCT03813108","phase":"NA","title":"Safety and Efficacy of NF135 CPS Immunization","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2019-04-01","conditions":"Malaria,Falciparum, Controlled Human Malaria Infection, Immunization; Infection","enrollment":43},{"nctId":"NCT03952650","phase":"PHASE1, PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":"Malaria","enrollment":252},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT04053907","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-08-15","conditions":"Malaria","enrollment":4000},{"nctId":"NCT05081089","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-12","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT04416945","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-09-20","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":31443},{"nctId":"NCT04310085","phase":"PHASE1","title":"Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-02-19","conditions":"Malaria,Falciparum, Parasitemia, Protozoan Infections","enrollment":16},{"nctId":"NCT03510481","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-14","conditions":"Malaria","enrollment":478},{"nctId":"NCT04877626","phase":"PHASE4","title":"Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2008-09","conditions":"P. Falciparum Malaria","enrollment":210},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04241705","phase":"NA","title":"Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia","status":"UNKNOWN","sponsor":"Armauer Hansen Research Institute, Ethiopia","startDate":"2020-01-20","conditions":"Malaria","enrollment":48960},{"nctId":"NCT03705624","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-06","conditions":"Malaria","enrollment":907},{"nctId":"NCT03163121","phase":"PHASE1","title":"Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2017-05-12","conditions":"Malaria","enrollment":67},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT02600767","phase":"NA","title":"Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-12","conditions":"Malaria","enrollment":79},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT00119145","phase":"PHASE4","title":"Kintampo Trial of Combination Therapy for Malaria","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-06","conditions":"Malaria","enrollment":510},{"nctId":"NCT02637128","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-03","conditions":"MALARIA, FALCIPARUM","enrollment":452},{"nctId":"NCT01150344","phase":"PHASE4","title":"Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-07","conditions":"Malaria","enrollment":317},{"nctId":"NCT01935882","phase":"PHASE2, PHASE3","title":"Low Dose Primaquine for Clearance of Gametocytes","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-09","conditions":"Malaria, Asymptomatic Malaria, Plasmodium Falciparum","enrollment":360},{"nctId":"NCT00808951","phase":"PHASE4","title":"In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-12","conditions":"Malaria","enrollment":440},{"nctId":"NCT01619878","phase":"PHASE2, PHASE3","title":"Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Acute Uncomplicated Falciparum Malaria","enrollment":20},{"nctId":"NCT01350856","phase":"PHASE4","title":"Tracking Resistance to Artemisinin (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-05","conditions":"Falciparum Malaria","enrollment":1700},{"nctId":"NCT00677833","phase":"PHASE2, PHASE3","title":"Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Malaria, Falciparum","enrollment":361},{"nctId":"NCT01998295","phase":"PHASE4","title":"Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine","status":"COMPLETED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2012-05","conditions":"Instantaneous Clearance","enrollment":45},{"nctId":"NCT01256658","phase":"PHASE4","title":"A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-11","conditions":"Malaria","enrollment":14075},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT01082731","phase":"PHASE4","title":"Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-11","conditions":"Malaria","enrollment":6},{"nctId":"NCT01082705","phase":"PHASE3","title":"Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-04","conditions":"P. Falciparum Malaria","enrollment":323},{"nctId":"NCT01103830","phase":"PHASE1","title":"Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2010-02","conditions":"Malaria, Falciparum","enrollment":287},{"nctId":"NCT01038063","phase":"PHASE4","title":"Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2010-10","conditions":"Malaria","enrollment":1200},{"nctId":"NCT01052584","phase":"NA","title":"Ethiopia Malaria Therapeutic Efficacy Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-10","conditions":"Malaria","enrollment":354},{"nctId":"NCT00304980","phase":"NA","title":"Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status","status":"TERMINATED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-03","conditions":"Plasmodium Falciparum Malaria","enrollment":3000},{"nctId":"NCT00386763","phase":"PHASE3","title":"Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Malaria, Falciparum","enrollment":890},{"nctId":"NCT00709969","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-07","conditions":"Plasmodium Falciparum Malaria","enrollment":310},{"nctId":"NCT00484900","phase":"PHASE3","title":"Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria","status":"COMPLETED","sponsor":"Dafra Pharma","startDate":"2006-05","conditions":"Plasmodium Falciparum Malaria","enrollment":1390},{"nctId":"NCT00529867","phase":"PHASE4","title":"Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Dafra Pharma","startDate":"2007-05","conditions":"Malaria, Falciparum","enrollment":267}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":513,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Artemether-lumefantrine: P. falciparum","genericName":"Artemether-lumefantrine: P. falciparum","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway. Used for Uncomplicated Plasmodium falciparum malaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}